• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肢体和骨盆软骨母细胞性骨肉瘤患者的治疗结果。

Treatment outcome of patients with chondroblastic osteosarcoma of the limbs and pelvis.

机构信息

Karolinska University Hospital, Stockholm, Sweden.

Karolinska Institutet, Stockholm, Sweden.

出版信息

Bone Joint J. 2019 Jun;101-B(6):739-744. doi: 10.1302/0301-620X.101B6.BJJ-2018-1090.R1.

DOI:10.1302/0301-620X.101B6.BJJ-2018-1090.R1
PMID:31154835
Abstract

AIMS

The aim of this study was to identify factors that determine outcomes of treatment for patients with chondroblastic osteosarcomas (COS) of the limbs and pelvis.

PATIENTS AND METHODS

The authors carried out a retrospective review of prospectively collected data from 256 patients diagnosed between 1979 and 2015. Of the 256 patients diagnosed with COS of the pelvis and the limbs, 147 patients (57%) were male and 109 patients (43%) were female. The mean age at presentation was 20 years (0 to 90).

RESULTS

In all, 82% of the patients had a poor response to chemotherapy, which was associated with the presence of a predominantly chondroblastic component (more than 50% of tumour volume). The incidence of local recurrence was 15%. Synchronous or metachronous metastasis was diagnosed in 60% of patients. Overall survival was 51% and 42% after five and ten years, respectively. Limb localization and wide surgical margins were associated with a lower risk of local recurrence after multivariable analysis, while the response to chemotherapy was not. Local recurrence, advanced patient age, pelvic tumours, and large volume negatively influenced survival. Resection of pulmonary metastases was associated with a survival benefit in the limited number of patients in whom this was undertaken.

CONCLUSION

COS demonstrates a poor response to chemotherapy and a high incidence of metastases. Wide resection is associated with improved local control and overall survival, while excision of pulmonary metastases is associated with improved survival in selected patients. Cite this article: 2019;101-B:739-744.

摘要

目的

本研究旨在确定影响肢体和骨盆软骨母细胞性骨肉瘤(COS)患者治疗结局的因素。

患者与方法

作者对 1979 年至 2015 年间确诊的 256 例骨盆和肢体软骨母细胞性骨肉瘤患者前瞻性采集的数据进行了回顾性分析。256 例骨盆和肢体软骨母细胞性骨肉瘤患者中,男性 147 例(57%),女性 109 例(43%)。发病时的平均年龄为 20 岁(0-90 岁)。

结果

所有患者中,82%对化疗反应不佳,这与肿瘤体积中存在主要软骨母细胞成分(超过 50%)有关。局部复发率为 15%。60%的患者诊断为同步或异时性转移。总生存率分别为 51%和 42%,5 年和 10 年后。多变量分析显示,肢体定位和广泛手术切缘与局部复发风险降低相关,而化疗反应与局部复发风险无关。局部复发、患者年龄较大、骨盆肿瘤和肿瘤体积大均对生存产生负面影响。在接受切除术的有限数量患者中,切除肺转移灶与生存获益相关。

结论

COS 对化疗反应差,转移发生率高。广泛切除与局部控制和总体生存改善相关,而在选择的患者中切除肺转移灶与生存获益相关。 引用本文:2019;101-B:739-744.

相似文献

1
Treatment outcome of patients with chondroblastic osteosarcoma of the limbs and pelvis.肢体和骨盆软骨母细胞性骨肉瘤患者的治疗结果。
Bone Joint J. 2019 Jun;101-B(6):739-744. doi: 10.1302/0301-620X.101B6.BJJ-2018-1090.R1.
2
Locally recurrent chondrosarcoma of the pelvis and limbs can only be controlled by wide local excision.骨盆和四肢局部复发性软骨肉瘤只能通过广泛局部切除来控制。
Bone Joint J. 2019 Mar;101-B(3):266-271. doi: 10.1302/0301-620X.101B3.BJJ-2018-0881.R1.
3
Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma.骨切除边缘及外科病理因素对肢体骨肉瘤保肢手术疗效的影响
Pediatr Blood Cancer. 2015 Feb;62(2):246-251. doi: 10.1002/pbc.25307. Epub 2014 Nov 8.
4
Evaluation of factors affecting survival rate in primary bone sarcomas with extremity and pelvis involvement.评估影响累及四肢和骨盆的原发性骨肉瘤生存率的因素。
Acta Orthop Traumatol Turc. 2020 May;54(3):234-244. doi: 10.5152/j.aott.2020.03.79.
5
[Surgical therapy of pelvis and spine in primary malignant bone tumors].[原发性恶性骨肿瘤的骨盆和脊柱外科治疗]
Orthopade. 2003 Nov;32(11):971-82. doi: 10.1007/s00132-003-0551-x.
6
Osteosarcoma of the pelvis: outcome analysis of surgical treatment.骨盆骨肉瘤:手术治疗的结果分析
Clin Orthop Relat Res. 2009 Feb;467(2):510-8. doi: 10.1007/s11999-008-0495-x. Epub 2008 Oct 15.
7
Secondary chondrosarcoma arising from osteochondroma: outcomes and prognostic factors.骨软骨瘤继发软骨肉瘤:结局和预后因素。
Bone Joint J. 2019 Oct;101-B(10):1313-1320. doi: 10.1302/0301-620X.101B9.BJJ-2019-0190.R1.
8
Clinical outcomes of 54 pelvic osteosarcomas registered by Japanese musculoskeletal oncology group.日本肌肉骨骼肿瘤学组登记的54例骨盆骨肉瘤的临床结果
Oncology. 2005;68(4-6):375-81. doi: 10.1159/000086978. Epub 2005 Jul 12.
9
Pelvic chondrosarcomas: surgical treatment options.骨盆软骨肉瘤:手术治疗选择。
Orthop Traumatol Surg Res. 2009 Oct;95(6):393-401. doi: 10.1016/j.otsr.2009.05.004. Epub 2009 Oct 3.
10
Do pathological fractures influence survival and local recurrence rate in bony sarcomas?病理性骨折会影响骨肉瘤的生存率和局部复发率吗?
Eur J Cancer. 2007 Sep;43(13):1944-51. doi: 10.1016/j.ejca.2007.07.004. Epub 2007 Aug 14.

引用本文的文献

1
A clinical prediction model for lung metastasis risk in osteosarcoma: A multicenter retrospective study.骨肉瘤肺转移风险的临床预测模型:一项多中心回顾性研究。
Front Oncol. 2023 Feb 10;13:1001219. doi: 10.3389/fonc.2023.1001219. eCollection 2023.
2
Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.骨肉瘤新辅助化疗的预后因素及组织病理学反应分析。
Jt Dis Relat Surg. 2023;34(1):196-206. doi: 10.52312/jdrs.2023.902. Epub 2023 Jan 14.
3
Timing of treatment in osteosarcoma: challenges and perspectives - a scoping review.
骨肉瘤治疗时机:挑战与展望——范围综述
BMC Cancer. 2022 Sep 10;22(1):970. doi: 10.1186/s12885-022-10061-0.
4
Analysis of the subcellular location of FAM230B and its interaction with premature miR-302b in osteosarcoma.分析 FAM230B 的亚细胞定位及其与骨肉瘤中早期 miR-302b 的相互作用。
J Bone Miner Metab. 2022 Jul;40(4):554-560. doi: 10.1007/s00774-022-01319-5. Epub 2022 May 31.
5
Osteosarcoma of the Pelvis: Clinical Presentation and Overall Survival.骨盆骨肉瘤:临床表现与总生存率
Sarcoma. 2021 Dec 6;2021:8027314. doi: 10.1155/2021/8027314. eCollection 2021.
6
Chemotherapy in the management of periosteal osteosarcoma: A narrative review.化疗在骨膜骨肉瘤治疗中的应用:一项叙述性综述。
J Bone Oncol. 2021 Sep 10;30:100389. doi: 10.1016/j.jbo.2021.100389. eCollection 2021 Oct.
7
The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma.活检标本中的破骨细胞数量可预测骨肉瘤新辅助化疗的疗效。
Sci Rep. 2021 Jan 21;11(1):1989. doi: 10.1038/s41598-020-80504-w.
8
Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.高级骨肉瘤肿瘤内异质性和免疫抑制微环境的单细胞 RNA 图谱。
Nat Commun. 2020 Dec 10;11(1):6322. doi: 10.1038/s41467-020-20059-6.
9
LINC00265 targets miR-382-5p to regulate SAT1, VAV3 and angiogenesis in osteosarcoma.LINC00265 通过靶向 miR-382-5p 调控 SAT1、VAV3 和骨肉瘤血管生成。
Aging (Albany NY). 2020 Aug 14;12(20):20212-20225. doi: 10.18632/aging.103762.
10
Artificial Intelligence (AI) Assisted CT/MRI Image Fusion Technique in Preoperative Evaluation of a Pelvic Bone Osteosarcoma.人工智能(AI)辅助CT/MRI图像融合技术在骨盆骨肉瘤术前评估中的应用
Front Oncol. 2020 Aug 4;10:1209. doi: 10.3389/fonc.2020.01209. eCollection 2020.